Dataset Information
Determinants of survival of people living with HIV/AIDS on antiretroviral therapy in Brazil 2006-2015.
Ontology highlight
ABSTRACT: Background
We compared AIDS-related mortality rates in people living with HIV (PLHIV) starting antiretroviral therapy (ART) in Brazil during 2006-2015 and examined associated risk factors .Methods
Data on ART use in PLHIV and AIDS mortality in Brazil was analysed with piecewise constant exponential models. Mortality rates and hazard ratios were estimated for 0-6, 6-12, 13-24, 25-36 and?>?36?months of ART use and adjusted for region, age, sex, baseline CD4 cell count and calendar year of ART initiation. An additional analysis restricted to those with data on risk group was also performed.Results
269,076 individuals were included in the analysis, 165,643 (62%) males and 103,433 (38%) females, with 1,783,305 person-years of follow-up time. 21,749 AIDS deaths were reported and 8898 deaths occurred in the first year of ART. The risk of death in the first six months decreased with early ART initiation; those starting treatment early with CD4?>?500 cells per ?L had a hazard ratio of 0.06 (95% CI 0.05-0.07) compared with CD4?ConclusionsEarly treatment is likely to have contributed to the improved survival in PLHIV on ART, with the greatest benefits observed in women, younger age-groups and those living in the North.
SUBMITTER: Mangal TD
PROVIDER: S-EPMC6396460 | biostudies-literature | 2019 Feb
REPOSITORIES: biostudies-literature
Publications
Determinants of survival of people living with HIV/AIDS on antiretroviral therapy in Brazil 2006-2015.
BMC infectious diseases 20190228 1
<h4>Background</h4>We compared AIDS-related mortality rates in people living with HIV (PLHIV) starting antiretroviral therapy (ART) in Brazil during 2006-2015 and examined associated risk factors .<h4>Methods</h4>Data on ART use in PLHIV and AIDS mortality in Brazil was analysed with piecewise constant exponential models. Mortality rates and hazard ratios were estimated for 0-6, 6-12, 13-24, 25-36 and > 36 months of ART use and adjusted for region, age, sex, baseline CD4 cell count and calendar ...[more]